Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes

Thumbnail
View/ Open

Show full item record

Author
McCubrey, James A.
URI
http://hdl.handle.net/10342/9631
Subject
 gene mutations; myelodysplastic syndromes (MDS); azacitidine and lenalidomide 
Date
2019-09
Citation:
APA:
McCubrey, James A.. (September 2019). Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes. Leukemia, (33:9), p.2276-2290. Retrieved from http://hdl.handle.net/10342/9631

Display/Hide MLA, Chicago and APA citation formats.

MLA:
McCubrey, James A.. "Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes". Leukemia. 33:9. (2276-2290.), September 2019. May 20, 2022. http://hdl.handle.net/10342/9631.
Chicago:
McCubrey, James A., "Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes," Leukemia 33, no. 9 (September 2019), http://hdl.handle.net/10342/9631 (accessed May 20, 2022).
AMA:
McCubrey, James A.. Response of High-Risk MDS to Azacitidine and Lenalidomide is Impacted by Baseline and Acquired Mutations in a Cluster of Three Inositide-Specific Genes. Leukemia. September 2019; 33(9) 2276-2290. http://hdl.handle.net/10342/9631. Accessed May 20, 2022.
Collections